Literature DB >> 18423074

The prevalence and workplace costs of adult attention deficit hyperactivity disorder in a large manufacturing firm.

R C Kessler1, M Lane, P E Stang, D L Van Brunt.   

Abstract

BACKGROUND: Little is known about the effects of adult attention deficit hyperactivity disorder (ADHD) on work performance or accidents-injuries.MethodA survey was administered in 2005 and 2006 to employees of a large manufacturing firm to assess the prevalence and correlates of adult ADHD. Respondents (4,140 in 2005, 4,423 in 2006, including 2,656 in both surveys) represented 35-38% of the workforce. ADHD was assessed with the World Health Organization (WHO) Adult ADHD Self-Report Scale (ASRS), a validated screening scale for DSM-IV adult ADHD. Sickness absence, work performance and workplace accidents-injuries were assessed with the WHO Health and Work Performance Questionnaire (HPQ).
RESULTS: The estimated current prevalence (standard error) of DSM-IV ADHD was 1.9% (0.4). ADHD was associated with a 4-5% reduction in work performance (chi12=9.1, p=0.001), a 2.1 relative-odds of sickness absence (chi12=6.2, p=0.013), and a 2.0 relative-odds of workplace accidents-injuries (chi12=5.1, p=0.024). The human capital value (standard error) of the lost work performance associated with ADHD totaled USD 4,336 (676) per worker with ADHD in the year before interview. No data were available to monetize other workplace costs of accidents-injuries (e.g. destruction of equipment). Only a small minority of workers with ADHD were in treatment.
CONCLUSIONS: Adult ADHD is a significantly impairing condition among workers. Given the low rate of treatment and high human capital costs, in conjunction with evidence from controlled trials that treatment can reduce ADHD-related impairments, ADHD would seem to be a good candidate for workplace trials that evaluate treatment cost-effectiveness from the employer's perspective.

Entities:  

Mesh:

Year:  2008        PMID: 18423074     DOI: 10.1017/S0033291708003309

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  43 in total

1.  Lisdexamfetamine dimesylate (vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder.

Authors:  David W Goodman
Journal:  P T       Date:  2010-05

2.  Memory-guided force output is associated with self-reported ADHD symptoms in young adults.

Authors:  Kristina A Neely; Amanda P Chennavasin; Arie Yoder; Genevieve K R Williams; Eric Loken; Cynthia L Huang-Pollock
Journal:  Exp Brain Res       Date:  2016-07-09       Impact factor: 1.972

3.  Childhood attention problems and socioeconomic status in adulthood: 18-year follow-up.

Authors:  Cédric Galéra; Manuel-Pierre Bouvard; Emmanuel Lagarde; Grégory Michel; Evelyne Touchette; Eric Fombonne; Maria Melchior
Journal:  Br J Psychiatry       Date:  2012-05-24       Impact factor: 9.319

4.  Persistent nonmedical use of prescription stimulants among college students: possible association with ADHD symptoms.

Authors:  Amelia M Arria; Laura M Garnier-Dykstra; Kimberly M Caldeira; Kathryn B Vincent; Kevin E O'Grady; Eric D Wish
Journal:  J Atten Disord       Date:  2010-05-19       Impact factor: 3.256

5.  The Estimated Annual Cost of ADHD to the U.S. Education System.

Authors:  Jessica A Robb; Margaret H Sibley; William E Pelham; E Michael Foster; Brooke S G Molina; Elizabeth M Gnagy; Aparajita B Kuriyan
Journal:  School Ment Health       Date:  2011-09-01

Review 6.  Cognitive characterization of adult attention deficit hyperactivity disorder by domains: a systematic review.

Authors:  Iban Onandia-Hinchado; Natividad Pardo-Palenzuela; Unai Diaz-Orueta
Journal:  J Neural Transm (Vienna)       Date:  2021-02-23       Impact factor: 3.575

7.  Update on adult attention-deficit/hyperactivity disorder.

Authors:  Paul Hammerness; Craig Surman; Katherine Miller
Journal:  Curr Neurol Neurosci Rep       Date:  2008-11       Impact factor: 5.081

Review 8.  European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD.

Authors:  Sandra J J Kooij; Susanne Bejerot; Andrew Blackwell; Herve Caci; Miquel Casas-Brugué; Pieter J Carpentier; Dan Edvinsson; John Fayyad; Karin Foeken; Michael Fitzgerald; Veronique Gaillac; Ylva Ginsberg; Chantal Henry; Johanna Krause; Michael B Lensing; Iris Manor; Helmut Niederhofer; Carlos Nunes-Filipe; Martin D Ohlmeier; Pierre Oswald; Stefano Pallanti; Artemios Pehlivanidis; Josep A Ramos-Quiroga; Maria Rastam; Doris Ryffel-Rawak; Steven Stes; Philip Asherson
Journal:  BMC Psychiatry       Date:  2010-09-03       Impact factor: 3.630

9.  The utility of attention-deficit/hyperactivity disorder screening instruments in individuals seeking treatment for substance use disorders.

Authors:  Elias Dakwar; Amy Mahony; Martina Pavlicova; Andrew Glass; Daniel Brooks; John J Mariani; John Grabowski; Frances Rudnick Levin
Journal:  J Clin Psychiatry       Date:  2012-11       Impact factor: 4.384

10.  First treatment contact for ADHD: predictors of and gender differences in treatment seeking.

Authors:  Elias Dakwar; Frances R Levin; Mark Olfson; Shuai Wang; Bradley Kerridge; Carlos Blanco
Journal:  Psychiatr Serv       Date:  2014-10-31       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.